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The Data Governance Act and the EU’s
move towards facilitating data sharing
Mahsa Shabani*
The implementation of the EU General Data
Protection Regulation (GDPR) has had
significant impacts on biomedical research,
often complicating data sharing among
researchers. The recently announced proposal
for a new EU Data Governance Act is a
promising step towards facilitating data
sharing, if it can interplay well with the
GDPR.
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I n an attempt to improve and increasedata sharing in the EU and to optimizethe re-use of personal and non-personal
data, the European Commission has recently




act). If approved, it will enable the creation
and regulation of “secure spaces” where
various types of data, including health data,
can be shared and re-used for both commer-
cial and altruistic purposes, including scien-
tific research. The Data Governance Act,
within the framework of a European Strat-
egy for Data, (https://ec.europa.eu/info/site
s/info/files/communication-european-strategy-
dat-19feb2020_en.pdf), would address some
of the shortcomings and drawbacks of the
current regulatory framework which holds
back sharing and re-using data for biomedi-
cal research purposes.
While the proposed Act would apply to
all types of personal and non-personal data,
the increasing demand for sharing health
data has most likely been a major rationale
for this new legislation of data governance.
Notably, sharing health and genetic data for
scientific research entails an extra layer of
complexity, owing to concerns over data
protection and privacy when sharing sensi-
tive personal data. Vice versa, there are also
concerns in the scientific community over
the negative impact of regulatory restrictions
on sharing health data in data-driven
biomedical research. The pressing question
here is how far the EU’s proposed legislative
and policy framework can offset either
concerns?
Researchers and data access barriers
Databases from hospitals, laboratories,
research institutes or patient registries have
become a crucial resource for biomedical
research, and the COVID-19 pandemic has
starkly highlighted the need for sharing
health data for epidemiological research
across borders. However, researchers face
significant barriers accessing health and
patient information owing to both an inade-
quate data-sharing infrastructure and a
restrictive regulatory framework, particu-
larly when data are shared across institu-
tions and countries (Bovenberg et al, 2020).
Sharing sensitive health data in the EU must
be compliant with the GDPR and data
protection principles, notably purpose limi-
tation, that is data can only be used for
specific purposes. In the context of biomedi-
cal research, however, it is often crucial to
be able to process data for multiple research
purposes without requiring explicit consent
for each downstream use.
Although many international and Euro-
pean funding organizations have stressed the
importance of sharing data related to COVID-
19 (https://wellcome.org/coronavirus-covid-
19/open-data), the guidelines provided by
data protection oversight bodies such as the




not significantly relaxed the conditions
regarding scientists’ access to and re-use of
such data. This article discusses how the
proposed Data Governance Act may address
some of the concerns related to the re-use




A major challenge for ensuring data protec-
tion and privacy is that sharing and
analysing data in biomedical research often
entails secondary uses or “further process-
ing” by other scientists across the world.
Adequate data governance mechanisms and
secure data-sharing platforms should be
adopted to ensure that such further process-
ing is compatible with the GDPR.
The proposed Act thus includes provi-
sions about data-sharing infrastructure,
intermediaries and providers of such data-
sharing services. These can assist data
holders, such as hospitals and research
institutions, as well as data subjects—that is
patients and research participants—with
sharing their personal and non-personal data
for commercial and altruistic purposes. The
activities of such data-sharing services
would be subject to oversight by competent
authorities according to the proposed Act.
Such platforms and other data-sharing
infrastructure should be compatible with the
GDPR, namely ensuring that databases can
only be accessed by authorized users for
authorized purposes. This aspect is crucial
in the context of biomedical research,
because sensitive health data from patients
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and research participants require a higher
level of protection to avoid potential abuse.
European Data Altruism Consent:
an opportunity for harmonizing
consent models?
Importantly, the proposed Act also aims to
introduce a uniform “European data altruism
consent form” for altruistic data re-use. It
defines “data altruism” and “general interest”
non-strictly as “the consent by data subjects
to process personal data pertaining to them,
or permissions of other data holders to allow
the use of their non-personal data without
seeking a reward, for purposes of general
interest, such as scientific research purposes
or improving public services”. The proposal
further expounds that this consent should be
considered as an additional legal certainty
specially in the context of scientific research
and contributes to additional transparency for
data subjects.
Introducing a new consent model for data
sharing can be both an opportunity and a
challenge for biomedical researchers. At first
sight, the proposed uniform consent model
can be seen as yet another requirement for
data sharing, on top of the other consent
requirements for research with human
subjects and for processing personal data.
On the other hand, a uniform European
consent for altruistic uses may become an
opportunity to harmonize legislation across
the EU Member States and thereby ease data
sharing at least within the EU.
One example of how research would bene-
fit from a uniform consent is the “1+ Million
Genomes” initiative of the European Commis-
sion (https://ec.europa.eu/digital-single-mark
et/en/european-1-million-genomes-initiative)
to facilitate access to large-scale genomic data
across Europe. One of the major obstacles for
this and other pan-European projects is to
coordinate regulatory frameworks, including
consent requirement, among the partners. In
this context, a harmonized approach to
consent is particularly useful as the GDPR
has left considerable room for implementa-
tion of the rules related to processing data for
scientific research.
In fact, as oversight bodies have not
supported a broad consent for scientific
research (EDPB, 2020), the Member States
have been left with the choice of either
requiring specific consent for research or
using other legal grounds such as public
interest as a lawful basis for processing data.
Depending on the relevant rules established
by national regulations, the latter may
remove the need for obtaining specific
consent for data processing in scientific
research. Although this option would seem
to ease the regulatory burden for scientists,
questions remain whether the principle of
transparency and patients’ right to self-deter-
mination are being adequately respected.
Patients and research participants have a
right to know how their data are being used
and for which purposes. While the consent
mechanism is admittedly far from perfect, it
still provides some legal certainty that indi-
viduals have been informed about use of
their data and exercised some level of
control on that matter.
The proposed Act can address the identi-
fied caveat on using public interest as a
basis for processing personal data. The
proposed uniform consent should bring
additional transparency for patients and
research participants and give them a choice
to opt in for sharing their data for altruistic
purposes. In that sense, a consent for altruis-
tic use can complement public interest as a
legal basis for using data in research, which
has been endorsed by the European Data
Protection Supervisor (EDPS) in their
preliminary opinion on the European Health
Data Space (EDPS, 2020). While the success
of the proposed uniform consent model
depends on how this will be implemented in
practice and how it will interplay with other
consent requirements, the rationale behind
it seems to align with the goal of empower-
ment of patients and participants.
Individual control on data and the
role of data cooperatives
The proposal has taken another step towards
empowerment of individuals, by recognizing
the role of intermediaries, such as data coop-
eratives, to support them on how their data
are being shared. Such data cooperatives can
assist to “negotiate terms and conditions for
data processing before they consent, in
making informed choices before consenting
to data processing, and allowing for mecha-
nisms to exchange views on data processing
purposes and conditions that would best
represent the interests of data subjects or
legal persons”, as stated in the text of the
proposed Act.
In recent years, the issue of empower-
ment of patients and research participants
has been accentuated notably by patient
groups who want better control over who
can access their data and for which
purposes. However, individual patients
often lack the adequate expertise to fully
understand the technicalities of the data-
sharing ecosystems. Adding this to the
imbalance of power between data subjects
and institutions who process data, the nego-
tiating power of individuals regarding the
terms and conditions of data use is signifi-
cantly restricted. In reality, individuals are
facing a so-called consent dilemma or a
take-it-or-leave-it option when consenting to
the use and re-use of their data. At times,
this has led to frustration among individuals
and patients’ groups who want to play a
more active role in research.
In response, a limited number of data
cooperatives, such as MIDATA (https://
www.midata.coop/en/home/) and SALUS
COOP (https://www.saluscoop.org), have
been established. MIDATA, a Swiss non-profit
cooperative, acts as a “trustee for data collec-
tion and guarantees the sovereignty of citi-
zens over the use of their data”. Participation
in the data cooperative would enable citizens
“to actively contribute to research as users of
the platform by providing access to data sets
and as cooperative members to control and
develop the cooperative” (Hafen, 2019).
Current examples include the use of the
MIDATA platform to collect data from Univer-
sity Hospital in Bern on patients with a gastric
bypass operation and University Hospital in
Zurich for research projects patients suffering
from multiple sclerosis (Hafen, 2019).
Notably, other emerging proposals such
as the Data Union (https://thedataunion.eu)
or the Data Dividend (Kelly, 2020) projects
can, in principle, also facilitate data sharing
by individuals for privately funded research.
Indeed, this could enable health and DNA
data markets for biomedical research spon-
sored by the private sector, where individu-
als share their data in exchange for financial
incentives (Ahmed & Shabani, 2019).
However, monetary incentives in health
research have raised ethical and legal
concerns, such as imposing undue influence
on individuals and questioning the validity
of their consent. The proposed Act has in
fact not addressed the issues related to
financial benefits for individuals who share
their data for commercial purposes. This
seems to be in line with the existing Euro-
pean approach which disfavours property
rights on personal data and is catious to
endorse monetizing personal data.
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Public trust on data-sharing platforms
The proposal Act’s aim to ease the flow of
data by providing a regulatory framework
for data-sharing infrastructure is a welcome
step towards orchestrating data sharing for
commercial and altruistic purposes. The Act
should however interplay with relevant
regulations such as the GDPR. It therefore
remains to be seen whether future regula-
tory steps and implementation of the Act—if
approved—would complement or compli-
cate the current EU regulatory landscape for
data sharing for research purposes.
The implementation of the GDPR has had
significant impacts on biomedical research,
mainly partly due to different consent
requirements and legal grounds for data
processing, which complicate data sharing
among researchers. Furthermore, the experi-
ence so far has shown that more than mere
adherence to data protection rules is needed
to guarantee the success of data-sharing
programmes. The enormous amount of
health and epidemiological data collected
during the COVID-19 pandemic is extremely
valuable for biomedical research and has
prompted the need to address all core
elements of a robust governance framework
for data. In particular, the tools andmeans for
empowering individuals to keep control over
how their data are being used and shared in a
transparent environment should be inte-
grated in future public health programmes for
sharing health data. This way, we can hope
that the upcoming data-sharing programmes
would succeed in wining public trust and
support by the general public, which would
greatly benefit biomedical research in turn.
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